Literature DB >> 11118308

Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages.

D K Deb1, K K Srivastava, R Srivastava, B S Srivastava.   

Abstract

The slow growth and highly infectious nature of Mycobacterium tuberculosis is a limiting factor in its use as test organism in high throughput screening for inhibitory compounds. To overcome these problems, use of surrogate strains and reporter genes have been considered. In this study, we have investigated the application of a fast growing nonpathogenic M. aurum expressing firefly luciferase in rapid screening of antituberculosis compounds in vitro and in infected macrophages using bioluminescence assay. The assay is based on luminescence determination using luciferin as substrate. Inhibition of bioluminescence was obtained with frontline antimycobacterial drugs like streptomycin, rifampicin, isoniazid, ethambutol, ofloxacin, and sparfloxacin at their reported MICs. Inhibition could be observed as early as 2 h in vitro and within 24 h in infected macrophages. The system can reliably be used in high throughput screening. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118308     DOI: 10.1006/bbrc.2000.3957

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter.

Authors:  Chartchai Changsen; Scott G Franzblau; Prasit Palittapongarnpim
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

2.  Double recombinant Mycobacterium bovis BCG strain for screening of primary and rationale-based antimycobacterial compounds.

Authors:  Vandana Singh; Rajesh Kumar Biswas; Bhupendra N Singh
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

3.  Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.

Authors:  Anthony Vocat; Ruben C Hartkoorn; Benoit Lechartier; Ming Zhang; Neeraj Dhar; Stewart T Cole; Claudia Sala
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

4.  Simple and rapid method to determine antimycobacterial potency of compounds by using autoluminescent Mycobacterium tuberculosis.

Authors:  Sreevalli Sharma; Ekaterina Gelman; Chandan Narayan; Deepa Bhattacharjee; Vijayashree Achar; Vaishali Humnabadkar; V Balasubramanian; Vasanthi Ramachandran; Neeraj Dhar; Neela Dinesh
Journal:  Antimicrob Agents Chemother       Date:  2014-07-21       Impact factor: 5.191

5.  Optimisation of bioluminescent reporters for use with mycobacteria.

Authors:  Nuria Andreu; Andrea Zelmer; Taryn Fletcher; Paul T Elkington; Theresa H Ward; Jorge Ripoll; Tanya Parish; Gregory J Bancroft; Ulrich Schaible; Brian D Robertson; Siouxsie Wiles
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

6.  Validation of a medium-throughput method for evaluation of intracellular growth of Mycobacterium tuberculosis.

Authors:  Daniel Eklund; Amanda Welin; Thomas Schön; Olle Stendahl; Kris Huygen; Maria Lerm
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

7.  Rapid measurement of antituberculosis drug activity in vitro and in macrophages using bioluminescence.

Authors:  Nuria Andreu; Taryn Fletcher; Nitya Krishnan; Siouxsie Wiles; Brian D Robertson
Journal:  J Antimicrob Chemother       Date:  2011-11-17       Impact factor: 5.790

Review 8.  In-vivo monitoring of infectious diseases in living animals using bioluminescence imaging.

Authors:  Pinar Avci; Mahdi Karimi; Magesh Sadasivam; Wanessa C Antunes-Melo; Elisa Carrasco; Michael R Hamblin
Journal:  Virulence       Date:  2017-12-08       Impact factor: 5.882

9.  Rapid in vivo assessment of drug efficacy against Mycobacterium tuberculosis using an improved firefly luciferase.

Authors:  Nuria Andreu; Andrea Zelmer; Samantha L Sampson; Melanie Ikeh; Gregory J Bancroft; Ulrich E Schaible; Siouxsie Wiles; Brian D Robertson
Journal:  J Antimicrob Chemother       Date:  2013-04-30       Impact factor: 5.790

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.